Key considerations in pharmacotherapy for type 2 diabetes mellitus: A multiple target organ approach

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 254-259

  Cornell, S ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

glucagon like peptide 1 receptor agonist; incretins; individualized; pathophysiology; pharmacotherapy; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ABDOMINAL DISCOMFORT; ANOREXIA; CLINICAL ASSESSMENT; COUGHING; DIARRHEA; DRUG EFFICACY; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RASH; REVIEW; RHINORRHEA; RISK ASSESSMENT; SATIETY; SIDE EFFECT; SORE THROAT; TASTE DISORDER; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INDIVIDUALIZED MEDICINE; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, GLUCAGON;

EID: 84861332255     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01302.x     Document Type: Review

References (51)

1. Russell-Jones D, Vaag A, Schmitz O, et al. (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia, 52, 2046-2055.
2. Field AE, Coakley EH, Must A, et al. (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine, 161, 1581-1586.
3. Ford ES, Williamson DF, Liu S, (1997) Weight change and diabetes incidence: findings from a national cohort of US adults. American Journal of Epidemiology, 146, 214-222.
4. Eckel RH, Grundy SM, Zimmet PZ, (2005) The metabolic syndrome. Lancet, 365, 1415-1428.
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52, 1210-1214.
6. Rodbard HW, Jellinger PS, Davidson JA, et al. (2009) Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice, 15, 540-559.
7. Mateo JF, Gil-Guillen VF, Mateo E, Orozco D, Carbayo JA, Merino J, (2006) Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. International Journal of Clinical Practice, 60, 422-428.
8. Resnick HE, Foster GL, Bardsley J, Ratner RE, (2006) Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care, 29, 531-537.
9. Niswender K, (2010) Diabetes and obesity: therapeutic targeting and risk reduction-a complex interplay. Diabetes Obesity and Metabolism, 12, 267-287.
10. Neumiller JJ, Campbell RK, (2009) Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy, 43, 1433-1444.
11. Christensen DB, Ferguson MS, Garrett DG, Bunting BA, Malone DC, Cranor CW, (2003) Studying pharmaceutical care: difficult but necessary. Journal of the American Pharmacists Association, 43, S36-S37.
12. Fera T, Bluml BM, Ellis WM, (2009) Diabetes ten city challenge: final economic and clinical results. Journal of the American Pharmacists Association, 49, 383-391.
13. Nauck MA, (2009) Unraveling the science of incretin biology. American Journal of Medicine, 122, S3-S10.
14. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368, 1696-1705.
15. Buse JB, Rosenstock J, Sesti G, et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 374, 39-47.
16. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B, (2001) Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 50, 1562-1570.
17. Hui H, Nourparvar A, Zhao X, Perfetti R, (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology, 144, 1444-1455.
18. Perfetti R, Zhou J, Doyle ME, Egan JM, (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 141, 4600-4605.
19. Rolin B, Larsen MO, Gotfredsen CF, et al. (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. American Journal of Physiology: Endocrinology and Metabolism, 283, E745-E752.
20. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Macconell L, (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Current Medical Research and Opinion, 24, 2943-2952.
21. Deacon CF, (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes, 53, 2181-2189.
22. Madsen K, Knudsen LB, Agersoe H, et al. (2007) Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. Journal of Medicinal Chemistry, 50, 6126-6132.
23. Kendall DM, Cuddihy RM, Bergenstal RM, (2009) Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. American Journal of Medicine, 122 (6 Suppl), S37-S50.
24. Marre M, Shaw J, Brandle M, et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26, 268-278.
25. DeFronzo RA, (2004) Pathogenesis of type 2 diabetes mellitus. Medical Clinics of North America, 88, 787-835.
26. Cornell S, Lullo A, (2009) Getting to goal for patients with type 2 diabetes: mission possible. Diabetes Trends, 21 (Suppl. A), 3-11.
27. American Diabetes Association (2009) Standards of medical care in diabetes-2009. Diabetes Care, 32 (Suppl. 1), S13-S61.
28. Skyler JS, Bergenstal R, Bonow RO, et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care, 32, 187-192.
29. DCCT/EDIC Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New England Journal of Medicine, 342, 381-389.
30. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
31. UK Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589.
33. Nathan DM, Buse JB, Davidson MB, et al. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 52, 17-30.
34. Morrow L, Hompesch M, Guthrie H, Chang D, Lyness W, Chatterjee DJ, (2010) Coadministration of liraglutide with insulin detemir does not affect the pharmacokinetics of either drug [abstract]. Diabetes, 59 (Suppl. 1), A178.
35. Burke SD, Cornell SA, (2008) Medication management in type 2 diabetes. Clinician Reviews, 18, 28-34.
36. Inzucchi SE, (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Journal of the American Medical Association, 287, 360-372.
37. Bolen S, Wilson L, Vassy J, et al. (2007) Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Comparative effectiveness review No. 8. Rockville, MD: Agency for Healthcare Research and Quality. Available at:.
38. Martin CL, (2007) Exploring the pharmacologic agents for treatment of type 2 diabetes. Diabetes Educator, 33 (Suppl. 1), 6-13.
39. Turner RC, Cull CA, Frighi V, Holman RR, (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). Journal of the American Medical Association, 281, 2005-2012.
40. UKPDS Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes, 44, 1249-1258.
41. Pratley RE, Nauck M, Bailey T, et al. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, 375, 1447-1456.
42. Nauck M, Frid A, Hermansen K, et al. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care, 32, 84-90.
43. Zinman B, Gerich J, Buse JB, et al. (2009) Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care, 32, 1224-1230.
44. Vilsboll T, Zdravkovic M, Le-Thi T, et al. (2007) Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care, 30, 1608-1610.
45. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 29, 2632-2637.
46. Lambeir AM, Durinx C, Scharpe S, De Meester I, (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences, 40, 209-294.
47. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 29, 2638-2643.
48. Mistry GC, Maes AL, Lasseter KC, et al. (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. Journal of Clinical Pharmacology, 48, 592-598.
49. Ziemer DC, Miller CD, Rhee MK, et al. (2005) Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educator, 31, 564-571.
50. Grant RW, Buse JB, Meigs JB, (2005) Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care, 28, 337-442.
51. Brown JB, Nichols GA, Perry A, (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care, 27, 1535-1540.